91 related articles for article (PubMed ID: 2474171)
1. Structural features of T-cell recognition: applications to vaccine design.
Berzofsky JA
Philos Trans R Soc Lond B Biol Sci; 1989 Jun; 323(1217):535-44. PubMed ID: 2474171
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of immunodominance in T-cell recognition, with applications to vaccine design.
Berzofsky JA
Princess Takamatsu Symp; 1988; 19():161-77. PubMed ID: 2479631
[TBL] [Abstract][Full Text] [Related]
3. Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans.
Berzofsky JA; Bensussan A; Cease KB; Bourge JF; Cheynier R; Lurhuma Z; Salaün JJ; Gallo RC; Shearer GM; Zagury D
Nature; 1988 Aug; 334(6184):706-8. PubMed ID: 2457809
[TBL] [Abstract][Full Text] [Related]
4. Protein antigenic structures recognized by T cells: potential applications to vaccine design.
Berzofsky JA; Cease KB; Cornette JL; Spouge JL; Margalit H; Berkower IJ; Good MF; Miller LH; DeLisi C
Immunol Rev; 1987 Aug; 98():9-52. PubMed ID: 2443443
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of T cell recognition with application to vaccine design.
Berzofsky JA
Mol Immunol; 1991 Mar; 28(3):217-23. PubMed ID: 1708102
[TBL] [Abstract][Full Text] [Related]
6. Progress toward an artificial vaccine for HIV: identification of helper and cytotoxic T-cell epitopes and methods of immunization.
Berzofsky JA
Biotechnol Ther; 1991; 2(1-2):123-35. PubMed ID: 1726961
[TBL] [Abstract][Full Text] [Related]
7. Features of T-cell recognition and antigen structure useful in the design of vaccines to elicit T-cell immunity.
Berzofsky JA
Vaccine; 1988 Apr; 6(2):89-93. PubMed ID: 2455388
[TBL] [Abstract][Full Text] [Related]
8. Antigenic peptide interaction with MHC molecules: implications for the design of artificial vaccines.
Berzofsky JA
Semin Immunol; 1991 Jul; 3(4):203-16. PubMed ID: 1932704
[TBL] [Abstract][Full Text] [Related]
9. Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide.
Cease KB; Margalit H; Cornette JL; Putney SD; Robey WG; Ouyang C; Streicher HZ; Fischinger PJ; Gallo RC; DeLisi C
Proc Natl Acad Sci U S A; 1987 Jun; 84(12):4249-53. PubMed ID: 2438696
[TBL] [Abstract][Full Text] [Related]
10. Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types.
Berzofsky JA; Pendleton CD; Clerici M; Ahlers J; Lucey DR; Putney SD; Shearer GM
J Clin Invest; 1991 Sep; 88(3):876-84. PubMed ID: 1715888
[TBL] [Abstract][Full Text] [Related]
11. Polyvalent synthetic vaccines: relationship between T epitopes and immunogenicity.
Jolivet M; Lise L; Gras-Masse H; Tartar A; Audibert F; Chedid L
Vaccine; 1990 Feb; 8(1):35-40. PubMed ID: 1690488
[TBL] [Abstract][Full Text] [Related]
12. A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees.
Perales MA; Schwartz DH; Fabry JA; Lieberman J
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):27-35. PubMed ID: 7648281
[TBL] [Abstract][Full Text] [Related]
13. Broad recognition of cytotoxic T cell epitopes from the HIV-1 envelope protein with multiple class I histocompatibility molecules.
Shirai M; Pendleton CD; Berzofsky JA
J Immunol; 1992 Mar; 148(6):1657-67. PubMed ID: 1371784
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B virus core and e antigen: immune recognition and use as a vaccine carrier moiety.
Schödel F; Peterson D; Milich D
Intervirology; 1996; 39(1-2):104-10. PubMed ID: 8957676
[TBL] [Abstract][Full Text] [Related]
15. Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity.
Kaumaya PT; Kobs-Conrad S; Seo YH; Lee H; VanBuskirk AM; Feng N; Sheridan JF; Stevens V
J Mol Recognit; 1993 Jun; 6(2):81-94. PubMed ID: 7508238
[TBL] [Abstract][Full Text] [Related]
16. Human immunodeficiency virus type 1 Nef epitopes recognized in HLA-A2 transgenic mice in response to DNA and peptide immunization.
Sandberg JK; Leandersson AC; Devito C; Kohleisen B; Erfle V; Achour A; Levi M; Schwartz S; Kärre K; Wahren B; Hinkula J
Virology; 2000 Jul; 273(1):112-9. PubMed ID: 10891413
[TBL] [Abstract][Full Text] [Related]
17. Identification of T-cell epitopes and use in construction of synthetic vaccines.
Cornette JL; Margalit H; DeLisi C; Berzofsky JA
Methods Enzymol; 1989; 178():611-34. PubMed ID: 2481216
[TBL] [Abstract][Full Text] [Related]
18. Role of preimmunization virus sequences in cellular immunity in HIV-infected patients during HIV type 1 MN recombinant gp160 immunization.
Kundu SK; Dupuis M; Sette A; Celis E; Dorner F; Eibl M; Merigan TC
AIDS Res Hum Retroviruses; 1998 Dec; 14(18):1669-78. PubMed ID: 9870321
[TBL] [Abstract][Full Text] [Related]
19. T cell multideterminant regions in the human immunodeficiency virus envelope: toward overcoming the problem of major histocompatibility complex restriction.
Hale PM; Cease KB; Houghten RA; Ouyang C; Putney S; Javaherian K; Margalit H; Cornette JL; Spouge JL; DeLisi C
Int Immunol; 1989; 1(4):409-15. PubMed ID: 2484961
[TBL] [Abstract][Full Text] [Related]
20. Exclusion of HIV epitopes shared with human proteins is prerequisite for designing safer AIDS vaccines.
Maksyutov AZ; Bachinskii AG; Bazhan SI; Ryzhikov EA; Maksyutov ZA
J Clin Virol; 2004 Dec; 31 Suppl 1():S26-38. PubMed ID: 15567091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
